LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Last trade$3.53
Day change-$0.295 (-7.72%)
Day range$3.47 – $3.86
Volume536,242
Market cap$120M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$120.03M
Price / earnings
—
Price / book
0.63×
Price / sales
9.71×
EV / sales
7.24×
EV / EBITDA
-0.6×
Profitability
Earnings per share
-$4.46
Return on assets
-66.85%
Return on equity
-73.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.66×
Quick ratio
11.39×
Cash ratio
1.72×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$127.7M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LENZ, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.38M
$5.49M
$1.9M
$1.59M
$12.5M
$5M
$0
$0
Cost of revenue
$454K
$280K
$1.08M
$418K
$0
$0
$0
$0
Gross profit
$2.93M
$5.21M
$825K
$1.17M
$12.5M
$5M
$0
$0
Selling, general and administrative
$35.85M
$39.38M
$44.96M
$39.63M
$27.6M
$12.8M
$11.11M
$9.36M
Research and development
$0
$0
$0
$0
$3.79M
$9.06M
$5.82M
$5.87M
Total operating expenses
$35.85M
$39.38M
$44.96M
$39.63M
$31.39M
$21.86M
$16.93M
$15.23M
Operating income
-$32.92M
-$34.17M
-$44.14M
-$38.46M
-$18.89M
-$16.86M
-$16.93M
-$15.23M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$30.97M
-$31.92M
-$41.49M
-$35.89M
-$16.7M
-$14.41M
-$14.62M
-$12.65M
Income taxes
$0
$3K
$0
$2K
$0
$500K
$0
$1K
Net income
-$30.97M
-$31.92M
-$41.49M
-$35.9M
-$16.7M
-$14.91M
-$14.62M
-$12.65M
Net income attributable to common shareholders
-$30.97M
-$31.92M
-$41.49M
-$35.85M
-$16.7M
-$14.91M
-$14.62M
-$12.46M
EBITDA
-$32.81M
-$34.06M
-$44.02M
-$38.36M
-$18.76M
-$16.84M
-$16.9M
-$15.2M
Basic earnings per share
-$0.99
-$1.02
-$1.32
-$1.15
-$0.59
-$0.53
-$0.53
-$0.45
Diluted earnings per share
-$0.99
-$1.02
-$1.32
-$1.15
-$0.59
-$0.53
-$0.53
-$0.45
Recent news
Company coverage with links to the original publishers.
Regeneron is expected to report Q3 2026 earnings of $16.08 per share (up 35.9% YoY) and revenues of $4.55 billion (up 21.2% YoY) on October 30. However, the company's Earnings ESP is -1.12%, indicating recent analyst bearishness, making it difficult to predict an earnings beat despite its Zacks Rank #3 rating. The company has a strong history of beating estimates, having surpassed consensus four times in the last four quarters.
Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance.
LENZ Therapeutics announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100) in Greater China through an Asset Purchase Agreement with Corxel Pharmaceuticals. The New Drug Application for LNZ100 was submitted to China's NMPA in September 2025 with approval anticipated in Q1 2027. LENZ is eligible to receive up to $85 million in regulatory and sales milestones plus tiered royalties on net sales.
The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.
Lenz Therapeutics stock plummeted 11.2% after missing Q4 earnings and sales expectations. The vision drug company reported a loss of $1.16 per share on $1.6 million in sales, versus analyst forecasts of $0.90 loss on $3.1 million in sales. Despite being on pace for 45,000 VIZZ prescriptions by end of Q1 2026, weak launch quarter uptake and quadrupled SG&A expenses disappointed investors. Management's lack of forward guidance further fueled the selloff.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.